10 new drugs hit TGA review list

A bumper list of 21 drugs has landed at the TGA, with 10 of those under evaluation, newcomers to the Australian market.

Sanofi's BTK inhibitor Cenrifki is being evaluated for use in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS) to help slow down disability progression, after being granted priority review.

The company's Altuviiio is also being evaluated to treat people with haemophilia A, to prevent or reduce bleeding episodes, treating bleeding when it happens, and managing bleeding during surgery.